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ABSTRACT
The efficacy of once-daily intravenous busulfan with fludarabine as a preparative regimen for partially matched
umbilical cord blood transplantation has not been formally studied. We randomized 10 adult patients with my-
eloid malignancies to receive either concurrent or sequential administration of intravenous busulfan 130 mg/m2
once daily  4 days and fludarabine 40 mg/m2 daily  4 days, followed by dual umbilical cord blood transplanta-
tion. The median combined cryopreserved total nucleated cell dose was 3.6  107/kg recipient body weight
(range: 2.8-4.5  107/kg). Graft-versus-host disease (GVHD) prophylaxis was provided by tacrolimus and my-
cophenolate mofetil (MMF). Donor-derived neutrophil recovery was observed in only 2 of 10 patients, resulting
in premature closure of the study as per graft failure stopping rules. We conclude that the myeloablative condi-
tioning regimen of once-daily intravenous busulfan with fludarabine provides insufficient immunosuppression
to allow for engraftment of partially matched, dual umbilical cord blood grafts.
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Since the publication by de Lima and colleagues in
2004, allogeneic stem cell transplant (SCT) condition-
ing consisting of once-daily intravenous busulfan and
fludarabine (Bu/Flu) has gained widespread popu-
larity [1]. Enthusiasm for this regimen is derived
from the fact that it provides a myeloablative dose of
Bu with exceptionally low early treatment-related
mortality (TRM) (3%). Pharmacokinetic studies dem-
onstrate predictable Bu blood levels with an area under
the curve (AUC) comparable to dose-adjusted oral ad-
ministration [1]. The regimen facilitates reliable en-
graftment of allogeneic peripheral blood or bone
marrow grafts from HLA-identical siblings or
matched unrelated donors. Widespread use of umbili-
cal cord blood as a stem cell source for adult patients in
need of allogeneic SCT has been hindered by TRM as
high as 63% following myeloablative conditioning and
high rates of graft failure because of an inadequatestem cell dose or immunologic rejection [2]. Prelimi-
nary evidence suggests that infusion of 2 umbilical
cord blood grafts improves engraftment in adult
recipients [3-5]. This prompted us to conduct a pro-
spective study of Bu/Flu preparation followed by
dual umbilical cord blood transplantation. Given its
nonspecific alkylating properties, we hypothesize that
Bu could interfere with deoxycytidine kinase-mediated
accumulation of intracellular F-ara-ATP, thereby
attenuating the immunosuppressive properties of the
Flu. We therefore randomized patients to sequential
versus concurrent administration of i.v. Bu and Flu.
PATIENTS, MATERIALS, AND METHODS
Patients
Tenpatients,median age 41 years, withmyeloidma-
lignancies (acutemyelogenous leukemia [AML], chronic
myelogenous leukemia [CML], or myelodysplastic591
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Patient No. Age Years/Sex Weight (kg) Disease Karyotype Status at Transplantation
1 40M 101 AML Inv16 CR2
2 21M 76 MDS (Hypocell.) 27 Aplastic
3 29M 96* CML(BC) Ph1 CP
4 49F 77 RAEB-2 Complex RAEB
5 32M 95 AML Normal PR†
6 44F 68 MDS RAEB-2 Inv3 RA
7 50F 93 AML Complex CR1
8 41M 92 AML Normal CR2
9 54F 76 CML Ph- CP
10 34M 67 RAEB-2 Complex RA
RAEB indicates refractory anemia with excess blasts; RA, refractory anemia; BC, blast crisis; CP, chronic phase; CR, complete remission—no
morphologic evidence of disease.
*Adjusted ideal body weight.
†Partial remission; 4% blasts with aberrant phenotype.syndrome [MDS]) provided informed consent for
participation in this randomized phase II study. Of
the AML patients, subject #4 had 4% residual blasts
at the time of transplantation. The remainder had no
detectable disease in the bone marrow. All MDS-
refractory anemia with excess blasts (RAEB)-2 patients
were downgraded to RA or RAEBwith pretransplanta-
tion therapy. The CML patients were in chronic phase
at the time of transplantation. The study was approved
by the institutional review board of the Duke Univer-
sity School of Medicine. Patient and disease character-
istics are demonstrated in Table 1.
Treatment Plan
Bone marrow conditioning consisted of Flu (Ber-
lex Laboratories, Wayne, NJ), 40 mg/m2/day  4
days and i.v. Bu (PDL Biopharma, Redwood City,
CA) 130 mg/m2/day  4 days. Patients were random-
ized to receive the drugs sequentially (Flu days 29 to
26; Bu days 25 to 22) or concurrently (days 25 to
22) [1]. Six patients received the drugs sequentially,
and 4 concurrently. Bu pharmacokinetic measure-
ments were performed on the first and fourth dose us-
ing a high-pressure chromatography assay as
previously described [6]. Patients were transplanted
with 2 partially matched umbilical cord blood grafts
that were at least 4 of 6 HLA-matched with the recip-
ient and 4 of 6 HLA matched between grafts (low res-
olution class I, high resolution class II) (Table 2).
graft-versus-host disease (GVHD) prophylaxis was
provided by tacrolimus dosed to achieve serum levels
of 10-20 ng/mL for 6 months and mycophenolate mo-
fetil (MMF) 1000 mg twice daily until 60 days follow-
ing transplantation. Donor chimerism was determined
by quantitative PCR amplification of informative mi-
crosatellites using DNA isolated from peripheral
blood or bone marrow CD31 and CD151 cells. Pri-
mary graft failure was defined as a patient who never
had detectable donor hematopoiesis. Secondary graft
failure was defined as a patient who had detectableearly donor hematopoiesis that was subsequently
lost. Patients with early disease relapse were deemed
not evaluable for graft failure.
Statistical Methods
A sample size of 24 for each arm of the study was
expected to provide enough power to detect a differ-
ence in rate of engraftment. Separate stopping rules
for primary or secondary graft failure were constructed
for each treatment arm using the Bayesian approach
that was based on an expected graft failure rate of
#20%. The parameters assumed a 5 0.8 and b 5
3.2. Three graft failure events among the first 6 pa-
tients enrolled in each arm triggered early stopping.
Early stopping rules were activated for both treatment
arms.
RESULTS AND DISCUSSION
All patients withAMLwere in remission at the time
of protocol entry. Patient 3 was in the second chronic
phase following induction therapy for lymphoid blast
crisis. All subjects with MDS with increased blasts un-
derwent induction chemotherapy and achieved apartial
response before protocol therapy. The median com-
bined umbilical cord blood cell dose was 3.6 107 total
nucleated cells/kg (Table 2). All grafts were at least 4 of
6HLAmatched with the recipient and each other. The
mean and median daily AUCs for Bu were 4185 and
4225 mmol-min (range: 2634-5278 mmol-min), respec-
tively. These values are nearly identical to those
reported by de Lima and colleagues [1], who, with the
same preparative regimen, achieved 100% donor en-
graftment using peripheral blood or bone marrow
grafts. Eight of 10 patients experienced primary or sec-
ondary graft failure, although2patientswere not evalu-
able for engraftment because of early disease relapse.
Only 2 of 10 patients achieved significant, yet incom-
plete donor hematopoietic chimerism (one on sequen-
tial, the other on the concurrent treatment arms).
Stopping rules for graft failure were met for both
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Patient
No.
Combined
Cord TNC/kg*
(107)
HLA-Matching†
(Cord #1 1
Cord #2)
Busulfan/
Fludarabine
Administration
Maximum
%Donor
Myeloid Chimerism
(Cord #1/#2)
Maximum %Donor
Lymphoid
Chimerism
(Cord #1/#2)
Current
Status Cause of Death
1 3.9 4/6 1 4/6 Concurrent 0/0 0/0 CR‡ day 700 —
2 3.4 4/6 1 4/6 Sequential 0/0 0/0 Dead day 89‡ Infection
3 2.8 4/6 1 4/6 Concurrent 0/0 0/0 Dead day 134‡ Infection
4 3.7 4/6 14/6** Sequential 6/6§ Dead day 137 Relapsed AML
5 3.9 6/6 1 6/6¶ Sequential 14/77 9/76 Dead day 118 Relapsed AML
6 4.5 4/6 1 4/6¶ Concurrent 25/52 5/20 Dead day 85 Relapsed AML
7 3.6 5/6 1 5/6 Sequential 0/9§ Dead day 33 Relapsed AML
8 3.5 4/6 1 4/6 Sequential 0/0 0/0 CR day 485t —
9 3.1 4/6 1 4/6 Concurrent 0/0 0/0 Dead day 108‡ Infection
10 3.9 4/6 1 4/6 Sequential 0/0 0/0 Dead day 88 Recurrent AML
AML indicates acute myelogenous leukemia.
*Cryopreserved.
†Low-resolution Class I, high-resolution Class II.
‡Posthaploidentical second transplant.
§Unselected bone marrow sample.
¶Cord #1 and #2 are Class I and Class II allele-level matched (probable siblings).
tPostautologous bone marrow rescue.
**5/6 in direction of rejection.arms of the trial, and thus there was no appreciable
difference in the probability of engraftment between
sequential or concurrent Bu/Flu administration.
Hematopoiesis was reconstituted in 5 patients follow-
ing a second transplant (4 using haploidentical grafts,
1 using an autologous backup graft), 2 of whom
have achieved long-term disease-free survival (DFS)
(Table 2). Three patients died of infection-related
complications and 5 from relapsed AML.
The poor engraftment that we observed with Bu/
Flu conditioning is in contrast to what has been re-
ported in adult recipients using dual umbilical cord
blood grafts and more immunosuppressive myeloabla-
tive or nonmyeloablative conditioning regimens [3-5].
This occurred despite providing an umbilical cord
blood graft of comparable HLA-matching and size.
In the study by Ballen and colleagues [4], engraftment
was achieved in 18 of 21 patients following reduced in-
tensity (RIC) preparation with melphalan 100 mg/m2,
Flu 150 mg/m2, and antithymocyte globulin (ATG).
Brunstein and colleagues [5] transplanted 110 patients,
most of whom required 2 umbilical cord blood units to
achieve a target cell dose of 3.0  107/kg. With a non-
myeloablative preparative regimen of cyclophospha-
mide 50 mg/kg, Flu 200 mg/m2 and total-body
irradiation (TBI) 200 cGy, the cumulative incidence
of sustained engraftment was 85%. In an earlier study,
the same group reported inferior engraftment when
nonmyeloablative doses of oral Bu (8 mg/kg) were
used instead of cyclophosphamide [7].
Following myeloablative, single-agent dosing of
Bu (16 mg/kg total dose) with autologous stem cell
support, Peters and colleagues [8] demonstrated spar-
ing of mature lymphoid cells in the peripheral blood.No significant change was observed in CD31,
CD41, or CD81T cell counts during the 26-day post-
transplant monitoring period. B cell immune function
was also spared. Although Gandhi and Plunkett [9]
demonstrate that Flu potentiates alkylator-induced cy-
totoxicity, the lack of Bu-induced lymphocytotoxicity
negates this potentially beneficial synergy and raises
significant questions surrounding the immunosup-
pressive properties of the Bu/Flu regimen. This is par-
ticularly important in the setting of umbilical cord
blood transplantation given the low stem cell dose
and donor/recipient HLA-discordance.
Sequencing in drug administration has been shown
to affect the efficacy of many combination therapies,
including those with Flu and Bu [9,10]. The cytotoxic-
ity of alkylating agents such as Bu is generally attrib-
uted to the formation of DNA crosslinks; however,
these drugs are also known to react with many other
biomolecules such as proteins, enzymes, and thiols
[11,12]. Flu-induced lymphocytotoxicity is contingent
on intracellular accumulation of F-ara ATP, which is
in turn dependent on the activity of intracellular deox-
ycytidine kinase [9]. Bu-induced interference of deox-
ycytidine kinase would therefore compromise the
immunosuppressive properties of Flu. It is for this rea-
son that we constructed a 2-armed trial, establishing
a cohort of patients who would receive Flu whose ac-
tivity could not be affected by coadministration of
Bu. Verification of Bu-induced deoxycytidine kinase
inhibition is planned through measurement of F-ara
ATP levels from samples collected following drug ad-
ministration. However, given the lack of reliable en-
graftment in both arms of the trial, the clinical
significance of this interaction is in question.
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size and the fact that despite being in remission at the
time of enrollment, half of the subjects had high-risk
cytogenetic abnormalities. Although early relapse
may serve to inflate the graft failure rate, it should be
noted that 4 of 5 patients with standard risk cytogenetic
abnormalities also experienced graft failure. TheM.D.
Anderson group ATG toBu/Flu as added immunosup-
pression for recipients of unrelateddonor grafts [1]. Be-
cause of concerns over impaired posttransplant
immune recovery, susceptibility to opportunistic infec-
tions, and prolonged platelet recovery, we opted not to
include ATG [13,14].
The Bu/Flu regimen is gaining popularity as an at-
tractive option to standard myeloablative conditioning
for allogeneic SCT. However, our data suggest that
given in the doses and schedules we tested, Bu/Flu
does not provide adequate immunosuppression to fa-
cilitate engraftment of partially matched umbilical
cord blood grafts and should not be used in this setting.
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